Review Series - January 4, 2018
Therapeutic Antibodies
Introduced by Drs. Freda K. Stevenson and Catherine M. Bollard, this series of 6 reviews written by leaders in the field describe the emerging mechanistic insights and therapeutic value of different classes of antibody therapy, including direct antibodies; “accelerator” antibodies against coreceptors; and antibodies reversing regulatory T-cell activity, for a variety of hematological malignancies.
Review Series Articles:
Introduction to a review series on therapeutic antibodies
Freda K. Stevenson and Catherine M. Bollard
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk, Paul G. Richardson and Fabio Malavasi
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez, Challice L. Bonifant and Stephen Gottschalk
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Sarah L. Buchan, Anne Rogel and Aymen Al-Shamkhani
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategiess
Cariad Chester, Miguel F. Sanmamed, Jun Wang and Ignacio Melero
CTLA-4: a moving target in immunotherapy
Behzad Rowshanravan, Neil Halliday and David M. Sansom
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette, Jianfeng Zhou and Ken H. Young